Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials
Authors' conclusion
Preliminary evidence from our analysis suggests that tirzepatide may not affect the risk ofcancer among individuals with T2DM. However, our results should be interpreted with extra caution, based on the several limitations of our "hypothesis-generating" analysis Future, well-designed studies are warranted to answer this important research question.
Study context
- Population
- Individuals with T2D in phase 2/3 randomized controlled trials (RCTs) of tirzepatide (up to 1st April 2024); study duration 36 to 72 weeks9 RCTs
- Comparison
- Tirzepatide vs comparators
- Outcome
- Risk for any type of cancer (primary safety endpoint)
Methodological detailsphase 2/3 RCTs, subgroup analyses by comparator type
- Phase 2/3 RCTs
- Subgroup analyses by comparator type
Pooled result
As reported in the abstract
Any cancer
- Tirzepatide does not increase the risk for any cancer (preliminary evidence)
Further pooled results
- Tirzepatide does not increase the risk of any of the specific cancer types
Original publication
Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. Published 24 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →